Psilocybin for depression: all studies (page 12)

Negative affective bias in depression following treatment with psilocybin or escitalopram – a secondary analysis from a randomized trial

Translational Psychiatry November 13, 2025 Bruna Giribaldi Cunha, David Nutt, Marieke Martens et al.

Abstract Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. This study compared psilocybin, with an established antidepressant, escitalopram, to investigate whether there are shared or distinct effects on emotional information processing....

DOI: 10.1038/s41398-025-03693-w Full text Psilocybin Major depressive disorder Escitalopram Depression economics +7

Metaanalyse: Wirksamkeit und Sicherheit von Psilocybin bei Major Depressionen

Fortschritte der Neurologie · Psychiatrie November 1, 2025

Wissenschaftler*innen der polnischen LUXMED Gruppe bewerteten mit einer Metaanalyse die Wirksamkeit und Sicherheit von Psilocybin bei der Behandlung von Major Depressionen (MDD), um die optimale Dosis und den optimalen Zeitpunkt für klinische Studien zu bestimmen.

DOI: 10.1055/a-2576-6069 Psilocybin Gynecology Drug prevention Double blind +1

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence

Psychedelics. October 28, 2025 James J Gattuso, Bilgenur Bezcioglu, Carey Wilson et al. 1 citation

Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsive disorder (OCD) and related conditions is increasingly recognised but remains understudied. We systematically evaluated clinical and preclinical evidence on psilocybin's effects on obsessive and compulsive behaviours with attention to translational...

DOI: 10.61373/pp025i.0044 Psilocybin Serotonergic Major depressive disorder Anxiety +12

Control group improvement lower in psilocybin trials for depression

The Brown University Psychopharmacology Update October 10, 2025

A meta‐analysis comprising 17 randomized trials has found that rates of control group improvement in depression studies were lower in psilocybin trials than in studies of esketamine or a selective serotonin reuptake inhibitor (SSRI). The results suggest that psilocybin's overall efficacy in the treatment of depression might be overestimated.

DOI: 10.1002/pu.31371 Psilocybin Treatment-resistant depression Depression economics Serotonin reuptake inhibitor +4

“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy

Psychedelic Medicine October 8, 2025 Elise C. Tarbi, Skye A. Miner, Kabir Nigam et al. 1 citation

Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to meet these existential needs, yet little is known about how patients describe this element of their cancer journey, and how it might be affected by PAT, especially in the group therapy context. Purpose: To explore how patients with cancer and...

DOI: 10.1177/28314425251370303 Psilocybin Existentialism Cancer Perspective graphical +6

Psilocybin-assisted psychotherapy in adults with depression – A literature review

Progress in Neuro-psychopharmacology and Biological Psychiatry September 24, 2025 Marie Celine Dorczok, Gloria Mittmann, Thomas Ettl et al. 2 citations

PAP combined with structured psychological support shows sustained reductions in depressive symptoms for treatment-resistant depression and major depressive disorder. Higher doses generally yield stronger benefits. While PAP holds significant potential as a holistic treatment, methodological limitations, such as heterogeneity in study designs, inconsistent levels of psychological support and...

DOI: 10.1016/j.pnpbp.2025.111508

Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds

EClinicalMedicine September 24, 2025 Megan Hosein, Matthew J Reid, Sarah A. Walser et al. 5 citations

The potential for psilocybin, and other psychedelic drugs, to fulfil a much needed and potentially transformative class of psychiatric treatments has garnered significant attention. Consequently, there has been a great deal of interest and investment in accelerating its development and potential implementation in routine clinical practice. However, the expanding scope of scientific discovery,...

DOI: 10.1016/j.eclinm.2025.103517 Full text

S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

OPAL (Open@LaTrobe) (La Trobe University) September 19, 2025

Supplement 1. Additional tables presenting primary and secondary outcomes, sensitivity analyses, and exploratory findings. Table A1. ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table A2. Adjusted ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table B1. Intent-To-Treat (ITT) Analysis for Demoralization Scale (DSII) and PTSD Checklist for DSM-5 (PCL-5). Table B2. Adjusted Intent-To-Treat (ITT)...

DOI: 10.1371/journal.pmed.1004519.s001

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

PLoS Medicine September 19, 2025 Benjamin R. Lewis, John Hendrick, Kevin Byrne et al. 5 citations

Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR...

DOI: 10.1371/journal.pmed.1004519

Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal

Journal of Affective Disorders September 16, 2025 Sami George Sabbah, Sophie Li, Sabrina Wong et al. 2 citations

Although these findings suggest psilocybin is associated with dynamic and temporally distinct neuroplastic changes linked to clinical improvement, several limitations must be acknowledged. Many studies reused overlapping datasets with high exploratory flexibility and risk of bias. The generalizability of results is therefore constrained. Future research should emphasize independent datasets,...

DOI: 10.1016/j.jad.2025.120335

Research